ImmunoGenesis
HOUSTON, TX · Biotechnology · 14 employees
ImmunoGenesis is a clinical-stage immuno-oncology biopharmaceutical company re-envisioning the treatment of "cold" tumors, particularly of immune-excluded tumors. Immune-excluded tumors, which account for more than half of all cancers, are characterized by having mechanisms of resistance that suppress the immune response; this subgroup is resistant to current immunotherapies. ImmunoGenesis is crea
Funding history
- Grant — $10.8M — Dec 2025
- Venture - Series Unknown — $5.7M — Jan 2025
- Venture - Series Unknown — $44.4M — Apr 2024
Recent signals
- May 28, 2026: ImmunoGenesis Appoints Claudio Dansky Ullmann as Chief Medical Officer
- Dec 04, 2025: Raised $10.8M in Grant
- Jan 15, 2025: Raised $5.7M in Venture - Series Unknown
- Apr 03, 2024: Raised $44.4M in Venture - Series Unknown
See plans & pricing → Track ImmunoGenesis’s funding, hiring, and signals — with verified contacts — on Fundz.